Research presented at the American Stroke Association’s International Stroke Conference in Los Angeles this February suggests a portable, low-field MRI system may soon improve access to care for patients who have trouble making it to a high-tech facility.
Stroke survivors who are optimistic about their recovery demonstrate lower levels of inflammation and physical disability than their less-cheerful counterparts, researchers reported at the Nursing Symposium of the American Stroke Association’s International Stroke Conference.
A shingles vaccine known as Zoster Vaccine Live can protect not only against a resurgence of the chickenpox virus, but also against stroke, according to research presented at the American Stroke Association’s International Stroke Conference this week in Dallas.
Seventy-one percent of young adults who use e-cigarettes believe it’s an unhealthy habit, according to a report from health data management firm Harmony Healthcare IT—but nearly 80% say they still feel safe vaping.
Major organizations including the American Heart Association and Campaign for Tobacco-Free Kids have issued critical statements following the Trump administration’s 2021 budget proposal, which aims to abolish the FDA Center for Tobacco Products and establish a new agency within the Department of Health and Human Services.
Physicians who treat individuals with AFib may mistake gastrointestinal bleeding as a side effect of their patients’ blood thinners when it may, in fact, be an early warning sign for bowel cancer, according to a new study.
A Massachusetts General Hospital physician was instrumental in getting two new medical emojis—an anatomically correct heart and a pair of lungs—approved for an update later this year, the Boston Globe reported Feb. 4.
A review published in Circulation: Cardiovascular Interventions Jan. 24 suggests adjunctive coronary atherectomy is a clinically useful and effective tool for treating severely calcified coronary lesions—but, in reality, it’s rarely used.
A recent meta-analysis published in the Journal of Vascular and Interventional Radiology supports evidence that paclitaxel-coated balloons may pose more risk than reward for patients with symptoms of critical limb ischemia.
Biotech company BioMarin Pharmaceutical is considering a price point of between $2 million and $3 million for its novel experimental gene therapy for hemophilia patients, the Wall Street Journal reported Jan. 16.